Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density.
Details
Serval ID
serval:BIB_DF413B23524D
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density.
Journal
Journal of Clinical Endocrinology and Metabolism
Contributor(s)
HORIZON Pivotal Fracture Trial, Black D., Cummings S., Delmas P., Eastell R., Reid I., Boonen S., Cauley J., Cosman F., Lakatos P., Leung PC., Man Z., Eriksen EF., Mesenbrink P., Lau E., Jasqui S., Mautalen C., Rosario-Jansen T., Caminis J., Raisz L., Bauer P., Compston J., DeMets D., Hirschberg R., Johnell O., Ralston S., Wallace R., Farkough M., Flood M., Bauer D., Palermo L., Lang T., Kerzberg E., Man Z., Mautalen C., Ridruejo M., Tate G., Velasco J., Hooper M., Kotowicz M., Nash P., Prince R., Roberts A., Sambrook P., Dobnig H., Finkenstedt G., Hoefle G., Klaushofer K., Pecherstorfer M., Peichl P., Body J., Boonen S., Devogelaer JP., Geusens P., Kaufman J., Brenol£££João£££ J. , Kochen J., Lederman R., Radominski S., Szejnfeld V., Zerbini C., Adachi J., Brown J., Choquette D., Hanley D., Josse R., Kendler D., Kremer R., Morin F., Olszynski W., Papaioannou A., Yuen CK., Chen B., Lin S., Casas N., Chalem M., Jaller J., Molina J., Aro H., Heikkinen J., Kröger H., Mäkinen L., Saltevo J., Salmi J., Välimäki M., Benhamou CL., Delmas P., Fardellone P., Werhya G., Allolio B., Felsenberg D., Happ J., Hartard M., Hensen J., Kaps P., Kekow J., Moericke R., Ortloff B., Schneider P., Wassenberg S., Leung PC., Balogh A., Gomor B., Hidvégi T., Koranyi L., Lakatos P., Poór G., Tulassay Z., Pollak RD., Eshed V., Foldes AJ., Ish-Shalom S., Vered I., Weiss M., Adami S., Barone A., Bianchi G., Giannini S., Isaia GC., Luisetto G., Minisola S., Molea N., Nuti R., Ortolani S., Passeri M., Rubinacci A., Seriolo B., Sinigaglia L., Choi WH., Kang MI., Kim GS., Kim HS., Kim YK., Lim SK., Son HY., Yoon HK., Abud C., Garcia P., Jasqui S., Ochoa L., Orozco J., Santos J., Reid I., Elle£££Sigbjørn£££ S. , Halse J., Høiseth A., Olav H., Røed£££Høivik Ingun£££ HI. , Skag A., Stakkestad J., Syversen U., Badurski J., Czerwinski E., Lorenc R., Marcinowska-Suchowierska E., Sawicki A., Supronik J., Ailamazyan E., Benevolenskaya L., Dreval A., Dvoretsky L., Dyomina R., Mazurov V., Melnichenko G., Mkrtoumyan A., Orlov-Morozov A., Ostroumova O., Pikhlak E., Shemerovskaya T., Shostak N., Skripnikova I., Smetnik V., Tsyrlina E., Usova G., Zalevskaya A., Zazerskaya I., Zotkin E., Ljunggren O., Lofgren J., Palmér M., Saaf M., Stenström M., Hasler P., Lamy O., Lippuner K., Merlin C., Rizzoli R., Theiler R., Tyndall A., Uebelhart D., Chen JF., Chen PQ., Chin LS., Hwang JS., Yang TS., Jirapinyo M., Sattaya R., Sriussadaporn S., Supasin S., Taechakraichana N., Wilawan K., Donnachie H., Eastell R., Fraser W., McLellan A., Reid D., Abruzzo J., Ackerman R., Adler R., Aloia J., Birbara C., Bode B., Bone H., Brandon D., Cauley J., Cosman F., Dionne D., Downs R.<Suffix>Jr</Suffix> , Dreyfus J., Elinoff V., Emkey R., Fanciullo J., Fiske D., Genaro P., Gollapudi M., Gordon R., Hennessey J., Howard P., Johnson K., Johnston C., Kagan R., Kafka S., Kaine J., Klein T., Koltun W., Leboff M., Levine B., Lewiecki EM., Lewis CE., Licata A., Lillestol M., Lubin B., Malamet R., Mangione A., Matkovic V., Mehta D., Miller P., Miller S., Murphy FT., Nattrass S., Podlecki D., Recknor C., Rosen C., Rowe D., Rude R., Schnitzer T., Sherrer Y., Silverman S., Stephenson K., Troupin B., Tucci J., Villareal R., Watts N., Weinstein R., Weinstein R., Weitz M., White R.
ISSN
1945-7197 (Electronic)
ISSN-L
0021-972X
Publication state
Published
Issued date
2009
Peer-reviewed
Oui
Volume
94
Number
9
Pages
3215-3225
Language
english
Notes
Publication types: Journal Article ; Multicenter Study
Publication Status: ppublish
Publication Status: ppublish
Abstract
CONTEXT: In the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly - Pivotal Fracture Trial (HORIZON-PFT), zoledronic acid (ZOL) 5 mg significantly reduced fracture risk.
OBJECTIVE: The aim of the study was to identify factors associated with greater efficacy during ZOL 5 mg treatment.
DESIGN, SETTING, AND PATIENTS: We conducted a subgroup analysis (preplanned and post hoc) of a multicenter, double-blind, placebo-controlled, 36-month trial in 7765 women with postmenopausal osteoporosis. Intervention: A single infusion of ZOL 5 mg or placebo was administered at baseline, 12, and 24 months.
MAIN OUTCOME MEASURES: Primary endpoints were new vertebral fracture and hip fracture. Secondary endpoints were nonvertebral fracture and change in femoral neck bone mineral density (BMD). Baseline risk factor subgroups were age, BMD T-score and vertebral fracture status, total hip BMD, race, weight, geographical region, smoking, height loss, history of falls, physical activity, prior bisphosphonates, creatinine clearance, body mass index, and concomitant osteoporosis medications.
RESULTS: Greater ZOL induced effects on vertebral fracture risk were seen with younger age (treatment-by-subgroup interaction, P = 0.05), normal creatinine clearance (P = 0.04), and body mass index >or= 25 kg/m(2) (P = 0.02). There were no significant treatment-factor interactions for hip or nonvertebral fracture or for change in BMD.
CONCLUSIONS: ZOL appeared more effective in preventing vertebral fracture in younger women, overweight/obese women, and women with normal renal function. ZOL had similar effects irrespective of fracture risk factors or femoral neck BMD.
OBJECTIVE: The aim of the study was to identify factors associated with greater efficacy during ZOL 5 mg treatment.
DESIGN, SETTING, AND PATIENTS: We conducted a subgroup analysis (preplanned and post hoc) of a multicenter, double-blind, placebo-controlled, 36-month trial in 7765 women with postmenopausal osteoporosis. Intervention: A single infusion of ZOL 5 mg or placebo was administered at baseline, 12, and 24 months.
MAIN OUTCOME MEASURES: Primary endpoints were new vertebral fracture and hip fracture. Secondary endpoints were nonvertebral fracture and change in femoral neck bone mineral density (BMD). Baseline risk factor subgroups were age, BMD T-score and vertebral fracture status, total hip BMD, race, weight, geographical region, smoking, height loss, history of falls, physical activity, prior bisphosphonates, creatinine clearance, body mass index, and concomitant osteoporosis medications.
RESULTS: Greater ZOL induced effects on vertebral fracture risk were seen with younger age (treatment-by-subgroup interaction, P = 0.05), normal creatinine clearance (P = 0.04), and body mass index >or= 25 kg/m(2) (P = 0.02). There were no significant treatment-factor interactions for hip or nonvertebral fracture or for change in BMD.
CONCLUSIONS: ZOL appeared more effective in preventing vertebral fracture in younger women, overweight/obese women, and women with normal renal function. ZOL had similar effects irrespective of fracture risk factors or femoral neck BMD.
Keywords
Aged, Aged, 80 and over, Body Mass Index, Bone Density/drug effects, Bone Density Conservation Agents/therapeutic use, Diphosphonates/therapeutic use, Double-Blind Method, Female, Femur Neck/drug effects, Femur Neck/metabolism, Hip Fractures/prevention & control, Humans, Imidazoles/therapeutic use, Spinal Fractures/prevention & control
Pubmed
Web of science
Open Access
Yes
Create date
18/02/2010 16:29
Last modification date
20/08/2019 17:03
Usage data
